{"DataElement":{"publicId":"3285124","version":"1","preferredName":"Disease or Disorder Best Outcome of Therapy Waldenstrom Macroglobulinemia Status Type","preferredDefinition":"A description of the best response to therapy for waldenstrom's macroglobulinem.","longName":"2946463v1.0:3282855v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2946463","version":"1","preferredName":"Disease or Disorder Best Outcome of Therapy","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._Having the most positive qualities._The result of therapy for a given disease or condition in a patient or group of patients.","longName":"2404658v1.0:3194600v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2404658","version":"1","preferredName":"Diseases and Disorders","preferredDefinition":"A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.","longName":"C2991","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"005AD6E5-0651-6A35-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-09","endDate":null,"createdBy":"PWEST","dateCreated":"2005-09-09","modifiedBy":"ONEDATA","dateModified":"2005-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3194600","version":"1","preferredName":"Best Outcome of Therapy","preferredDefinition":"Having the most positive qualities.:The result of therapy for a given disease or condition in a patient or group of patients.","longName":"C25432:C18919","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Best","conceptCode":"C25432","definition":"Having the most positive qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Outcome of Therapy","conceptCode":"C18919","definition":"The result of therapy for a given disease or condition in a patient or group of patients.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D80CD45-BE7A-5B19-E040-BB89AD430E80","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"ZHANGW","dateCreated":"2011-03-02","modifiedBy":"ONEDATA","dateModified":"2011-03-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"747EBAC6-25E8-A734-E040-BB89AD43588E","latestVersionIndicator":"Yes","beginDate":"2009-09-26","endDate":null,"createdBy":"MOROZOFA","dateCreated":"2009-09-26","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3282855","version":"1","preferredName":"Waldenstrom Macroglobulinemia Status Type","preferredDefinition":"Lymphoplasmacytic lymphoma associated with bone marrow involvement and IgM monoclonal gammopathy._A condition or state at a particular time._Type; a subdivision of a particular kind of thing.","longName":"3282855v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Not assessed","valueDescription":"Negation Assessment","ValueMeaning":{"publicId":"3049794","version":"1","preferredName":"Negation Assessment","longName":"3049794","preferredDefinition":"An operation in which a term denies or inverts the meaning of another term or construction.: Having determined the value, significance, or extent of.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Assessment","conceptCode":"C25217","definition":"The final result of a determination of the value, significance, or extent of.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"836E0020-994D-2647-E040-BB89AD435E03","latestVersionIndicator":"Yes","beginDate":"2010-04-04","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2010-04-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ADDABD7C-89C3-A79E-E040-BB89AD43539E","beginDate":"2011-09-26","endDate":null,"createdBy":"NYCHM","dateCreated":"2011-09-26","modifiedBy":"ONEDATA","dateModified":"2011-09-26","deletedIndicator":"No"},{"value":"Continued complete remission","valueDescription":"Continued complete remission","ValueMeaning":{"publicId":"3691833","version":"1","preferredName":"Continued complete remission","longName":"3691833","preferredDefinition":"The patient had achieved a complete response; received more therapy and continued in complete response.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D71B7975-BFCB-8894-E040-BB89AD4376CE","latestVersionIndicator":"Yes","beginDate":"2013-03-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-03-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F7B75D19-96FE-3807-E040-BB89AD43680F","beginDate":"2014-04-23","endDate":null,"createdBy":"SORENSENS","dateCreated":"2014-04-23","modifiedBy":"ONEDATA","dateModified":"2014-04-23","deletedIndicator":"No"},{"value":"Progressive disease","valueDescription":"Progressive disease","ValueMeaning":{"publicId":"4280544","version":"1","preferredName":"Progressive disease","longName":"4280544","preferredDefinition":"At least 25% increase in serum monoclonal IgM by protein electrophoresis confirmed by a second measurement or progression of clinically significant findings due to disease (ie, anemia, thrombocytopenia, leukopenia, bulky adenopathy / organomegaly) or symptoms (unexplained recurrent fever of at least 38.4° C, drenching night sweats, at least 10% body weight loss, or hyperviscosity, neuropathy, symptomatic cryoglobulinemia, or amyloidosis) attributable to MAC / LPL.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F7B89B3A-5C0F-9E5D-E040-BB89AD433EA0","latestVersionIndicator":"Yes","beginDate":"2014-04-23","endDate":null,"createdBy":"SORENSENS","dateCreated":"2014-04-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F7B89B3A-5C27-9E5D-E040-BB89AD433EA0","beginDate":"2011-09-22","endDate":null,"createdBy":"SORENSENS","dateCreated":"2014-04-23","modifiedBy":"ONEDATA","dateModified":"2014-04-23","deletedIndicator":"No"},{"value":"Partial remission","valueDescription":"Partial remission","ValueMeaning":{"publicId":"4280578","version":"1","preferredName":"Partial remission","longName":"4280578","preferredDefinition":"At least 50% reduction of serum monoclonal IgM concentration on protein electrophoresis and at least 50% decrease in adenopathy / organomegaly on physical examination or on CT scan. No new symptoms or signs of active disease.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F7B95169-5169-B3EF-E040-BB89AD434E53","latestVersionIndicator":"Yes","beginDate":"2014-04-23","endDate":null,"createdBy":"SORENSENS","dateCreated":"2014-04-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F7B95169-5181-B3EF-E040-BB89AD434E53","beginDate":"2011-09-22","endDate":null,"createdBy":"SORENSENS","dateCreated":"2014-04-23","modifiedBy":"ONEDATA","dateModified":"2014-04-23","deletedIndicator":"No"},{"value":"Complete remission","valueDescription":"Complete remission","ValueMeaning":{"publicId":"4280576","version":"1","preferredName":"Complete remission","longName":"4280576","preferredDefinition":"Disappearance of monoclonal protein by immunofixation; no histologic evidence of bone marrow involvement, resolution of any adenopathy / organomegaly (confirmed by CT scan), or signs or symptoms attributable to MAC / LPL. Reconfirmation of the CR status is required at least 6 weeks apart with a second immunofixation.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F7B95169-5124-B3EF-E040-BB89AD434E53","latestVersionIndicator":"Yes","beginDate":"2014-04-23","endDate":null,"createdBy":"SORENSENS","dateCreated":"2014-04-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F7B95169-513C-B3EF-E040-BB89AD434E53","beginDate":"2011-09-22","endDate":null,"createdBy":"SORENSENS","dateCreated":"2014-04-23","modifiedBy":"ONEDATA","dateModified":"2014-04-23","deletedIndicator":"No"},{"value":"Minor remission / stable disease","valueDescription":"Minor remission / stable disease","ValueMeaning":{"publicId":"4280577","version":"1","preferredName":"Minor remission / stable disease","longName":"4280577","preferredDefinition":"At least 25% but less than 50% reduction of serum monoclonal IgM by protein electrophoresis. No new symptoms or signs of active disease. Or a less-than-25% reduction and less-than-25% increase of serum monoclonal IgM by electrophoresis without progression of adenopathy / organomegaly, cytopenias, or clinically significant symptoms due to disease and/or signs of MAC / LPL.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F7B95169-5146-B3EF-E040-BB89AD434E53","latestVersionIndicator":"Yes","beginDate":"2014-04-23","endDate":null,"createdBy":"SORENSENS","dateCreated":"2014-04-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F7B95169-515F-B3EF-E040-BB89AD434E53","beginDate":"2011-09-26","endDate":null,"createdBy":"SORENSENS","dateCreated":"2014-04-23","modifiedBy":"ONEDATA","dateModified":"2014-04-23","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3282854","version":"1","preferredName":"Waldenstrom Macroglobulinemia Status Type","preferredDefinition":"Lymphoplasmacytic lymphoma associated with bone marrow involvement and IgM monoclonal gammopathy.:A condition or state at a particular time.:Type; a subdivision of a particular kind of thing.","longName":"C80307:C25688:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Waldenstrom Macroglobulinemia","conceptCode":"C80307","definition":"Lymphoplasmacytic lymphoma associated with bone marrow involvement and IgM monoclonal gammopathy.","evsSource":"RADLEX_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD8A62AE-1555-5C54-E040-BB89AD431ABB","latestVersionIndicator":"Yes","beginDate":"2011-09-22","endDate":null,"createdBy":"NYCHM","dateCreated":"2011-09-22","modifiedBy":"ONEDATA","dateModified":"2011-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD8A62AE-1566-5C54-E040-BB89AD431ABB","latestVersionIndicator":"Yes","beginDate":"2011-09-22","endDate":null,"createdBy":"NYCHM","dateCreated":"2011-09-22","modifiedBy":"KUMMEROA","dateModified":"2021-01-05","changeDescription":". 2021-1-5 ak OK to release per WZ.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2695319","version":"1","longName":"NMDP: CDEs to review","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"3279309","version":"1","longName":"2119r1: Waldenström's Macroglobulinemia Post-HSCT Data","context":"NHLBI"},{"publicId":"3279271","version":"1","longName":"Disease Status","context":"NHLBI"}]}],"AlternateNames":[{"name":"mac_post_tx_bst_rspn_kn","type":"NMDP_FN","context":"NHLBI"},{"name":"mac_post_dx_bst_rspn_kn","type":"NMDP_FN","context":"NHLBI"},{"name":"MACpost_mac_best_resp","type":"NMDP_FN","context":"NHLBI"},{"name":"MACpost_therapy_multi_mac_stat","type":"NMDP_FN","context":"NHLBI"},{"name":"MACpre_therapy_multi_mac_stat","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What was the Waldenstrom Macroglobulinemia best response?","type":"Alternate Question Text","description":"What was the Waldenstrom Macroglobulinemia best response?","url":null,"context":"NHLBI"},{"name":"What was the best response to HSCT?","type":"Alternate Question Text","description":"What was the best response to HSCT?","url":null,"context":"NHLBI"},{"name":"Best response to line of therapy:","type":"Alternate Question Text","description":"Best response to line of therapy:","url":null,"context":"NHLBI"},{"name":"What was the best outcome of","type":"Preferred Question Text","description":"What was the best outcome of therapy for Waldenstrom's macroglobulinemia?","url":null,"context":"NHLBI"},{"name":"What was the best response to HCT?","type":"Alternate Question Text","description":"What was the best response to HCT?","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ADDA2383-FF71-EB66-E040-BB89AD4323C3","latestVersionIndicator":"Yes","beginDate":"2011-09-26","endDate":null,"createdBy":"NYCHM","dateCreated":"2011-09-26","modifiedBy":"KUMMEROA","dateModified":"2021-01-05","changeDescription":". 2021-1-5 ak OK to release per WZ. System generated def displayed as alt def. AK 11/17/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}